Unjha Formulations Reports Positive Q3 Results, EPS Increases to Rs 0.87

Unjha Formulations, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending December 2023. The company has shown a positive performance in this quarter, with a score of 6 compared to -5 in the previous 3 months. One of the key highlights of the financial report is the growth in net sales, which has increased by 31.67% year on year to reach Rs 10.31 crore. This indicates a positive trend in the company's sales in the near term. Additionally, Unjha Formulations has also seen a significant improvement in its operating profit, with the highest PBDIT (Profit Before Depreciation, Interest, and Taxes) of Rs 0.42 crore in the last five quarters. The company's PBT (Profit Before Tax) and PAT (Profit After Tax) have also shown an upward trend, with the highest figures of Rs 0.39 crore in the last five quarters. The company's earnings per share (EPS) have also increased to Rs 0.87, indicating a higher profitability and value creation for its shareholders. However, the financial report also highlights a concern in the form of a decrease in cash and cash equivalents, which have reached a low of Rs -0.03 crore in the last six half-yearly periods. This indicates a deteriorating short-term liquidity for Unjha Formulations. Based on these financial results, MarketsMOJO has given a 'Sell' call for Unjha Formulations' stock. Investors are advised to carefully consider these financials before making any investment decisions.